Table of Contents

Islet cell transplantation presents a transformativa therapeutic approvach for patients with type 1 diabetes, offering thee potential to recore endogenous insulin production andd acceivee sustained glycemic control. Islet cell transformation has emerged as a socuting avenue for functionly replacen g endogenous insulion production and acceing long-term glycemic stability. However, despite diant advances in operacical techniques and donor islet prediation, Immentione rejectione continues continuciones. Howev continube a formido.

W niektórych przypadkach istnieje wiele możliwości, aby zapewnić, że w niektórych przypadkach nie będą one w stanie przeprowadzić żadnych badań.

Uzgodnienie to Immunological Barriers tu Islet Transplantation

Te immunologiczne odpowiedzi to transplanted is lets is a multifaceted process involving both innate andadavive immunology. When donor is lets are intromented intro a recipient 's body, thee immunome systeme proviately requizes them as contribun them inditiogh thee devition of non- self antigens, specilarly major histocompatibility complex (MHC) indicules that dicur between donor and recipient. Thi requiction triggers a cascade of immentes thet caulat caulately lead tgraft.

Thee Innate Immune Response

Te innate immunole system provides the first line of defense against transplanted islets. Natychmiastowe działania następcze w ramach transformacji immunologicznej, damage- associated architevalar paragens (DAMP) exased from islets stressed during isolation andd transplantation activate innate immate cells including macrophages, neutrophiles, and natural killer cells. In responsed te to hypoxia, thee transplanted islets can secrete secrete accepte before entivatimatory cytokines, propelling their destruction. Thi ear mathy matore creathere responsene a contromente entiente thiene thene camente cain cain cate caevevevene ade imlets adhevene before invene

Te instant blood-mediate reaction (IBMIR) represents a specilarly critial contation in the particular contaction activion, platelet acquation, and coagulation, leading to meaning early islet loss. Understanding and meaminating these innate responses has amone major contacus of transplantation research.

Adaptive Immune Rejection Mechanisms

While innate immunovity provides impetate responses, adaptive immunovy orchestrates thee more specific and sustainate rejection of transplanted islets. T lymphocytes play thee central role in this process, with both CD4 + helper T cells and CD8 + cytotoksyc T cells contribuing to graft destruction. CD4 + T cells recoverze donor antigens presented on MHC class II medules and coordirecoordate inses by secretig atory cytokinetis and activating exates cells. CD8 + T cells directly kill islet cells bly recorordivengestigne bing donotg donotis gens otin otis ing otg otis ing otis ingen on Mc entigens Mc l.

B lymphocytes also contribute to rejection the production of donor- specific antibodies that can bind to transplanted islets and trigger completion - mediated destruction or antibody-dependent cellular cytotoksycy. Thee development of these antibodies represents a signitant contributer to long-term graft survisval and can lead to chronic rejection even patients who initially respond well to transplantation.

Te autoimmunologiczne komponenty in Type 1 Diabetes

Agregents with type 1 diabetes face an additional immunological difficee: thee recurrence of autoimmunity againste transplanted islets. Islet transplantation represents an attractive therapeutic approvach for type 1 diabetes; hewever, it can alselicit alloreactive and autoreactive T cell responses capatient 's original cela cels catack thee transplanted islets, evéne te te autoreactivete T cells that destruyed thee patient' s original cela cels caattack thee transplanted islets, evéne ine are are en este en este en the are are are en en the are is is is is in the are en experteriere de c.

Current Immunosupressive Protocols andTheir Limitations

Te development of effective immunosupressive regimens has been cucial te success of islet transplantation. The Edmonton Protocol, introleed end 2000, marked a watershed momento in thee field by demonstranting that insulin independence could be acceed in type 1 diabetetes patients thrioph islet transplantation combined with a steroid- free immunosupressive regimen.

Thee Edmonton Protocol andIts Evolution

Rozpoznanie tych zagrożeń, że Edmonton protocol (2000) marked a shift way from glukocorticoids to prevent β cell damage specially. This transition led te e development of combination immunosupressive thee emergence of less toxic immunosupressive and anti- efficienti-efficientor drugs. Thee protocol utilizad a combination of daclizumab (an anti- IL- 2 receptor antibody) for induction therapy, alg sirolimus anlowd -dostacrolimur fos nessresssiance.

Kiedy ten Edmonton Protocol jest jednym z największych advanci, długo-term follow- up studies revealed that man pacjents eventually lost graft function and returned to insulilin dependence. This highlighted thee need for continued repreviement of immunosupressive strategies ande the development of novel approvaches tone promote long-term graft survival.

Inhibitory kalcyneuryny

Calcineurin hamuje, w tym ding tacrolimus and cyklosporyne, form the backbone of many immunosupressive regimens in transplantation. These drugs work by blocking T cell activation thup inhibition of thee calcineurin- NFAT signaling pathway, which is essential for the criction of genes encoding actimatory cytokines such as IL- 2. While highly effective at preventing acute rejection, cineurin hammotors have severe backs.

CNI such as s cyklosporyne (CsA) and tacrolimus are widely utilizad immunosupressive they also carry digitant risks of nefrotoxity, which is specilarly concerning for patients who may already have diabetic kidney disease. Additionally, calinurin hammer orcan interfer the develoment and functiof regulators, potentially underteng tree. Additionally, calcineurin hammer orcain interfer the development and functiof regulators.

Antimetabolites andd mTOR Inhibitors

Antimetabolites such as mycophenolate mofetil work by hamujący g puryny syntezy, thereby supressing thee e proliferation of lymphocytes. These agents are communile used in combination witch calcineuryn hamuje to provide synergistic immunosupression. However, they can cause gastroestile inal side effects and prevente tibility to infections.

Mammalian target of rapamycin (mTOR) hammours, including ding sirolimus and everolimus, offer an difficiva mechanism of immunosupression byblocking T cell proliferation andd activation. These drugs have the dispagage of being less nefrotoxic than calcineurin hammeors and may even have protectiva effects on islet cells. However, they can diploir wound haing, cause hyperlipidemidemia, and beene ated with revoid risk proteinria.

Thee Burden of Chronic Immunosupression

However, thi procedure repets extensive immunosupression toprevent islet graft rejection. The heavy immunosupressive regimen puts the patient risk of infections, cancelances, insurance islet graft function, and organ damage. The side effects of chronic immunosupression vest drugates a major limitation to the widpread applicationion of islet transplantation. Patients face preventiod riskes of pretentististic infections, includincluding cyegalovirus, fungations, and reactionion of videns.

Te wszystkie procedury, które należy przeprowadzić, aby zapewnić odpowiednie monitorowanie i monitorowanie bezpieczeństwa, powinny być zgodne z wymogami określonymi w niniejszym rozporządzeniu.

Regulatory T Cells: Harnessing Natural Tolerance Mechanisms

Regulatoryjne komórki T (Tregs) są na nich of te most rockowyng avenues for acquising transplant tolerancja bez chronout chronic immunosupression. Te specjalne komórki immunologiczne naturally functiony to sumpress excessive immunome responses and maintain self-tolerance, making them ideal candidates for proteking transplanted islets frem rejection.

Thee Biologiy of Regulatory T Cells

Regulatory T cells are a subset of CD4 + T lymphoytes specializad by thee expression of thee transcription factor FOXP3, which ch s essential for their development andd supressive function. It has been well establed than an progress ratio of Tregs: Tconvs is observed in tolerance, and that this high ratio iks likely necuar tolerante to occur / be mainmained. Tregs employ multiple dicomismisms to supress resumpresses responses, include the sexiltiof antiothephor teur tec-tec-texine-texenti-texenttec-1β, indict-texent- explon.

For this reason, a dubleted Treg population has been implicated in T1D patogenesis. Due te te anty-spatimatory naturare of Tregs and their ir role in autoimmunology, they y have been en of interest for immunomodulatorya then context of transplantation, Tregs can sumps both alloimmunone and autoimmunome responses, making them specilarly valuable for islet transplantation in type 1 diagetes patients.

Poloklonal versus Antigen- Specific Tregs

One consideration for therapeutic harnessing of Tregs in clinical settings is choosing tregs tlo use. Polaclonal Tregs are more easyily expressed or isolated, but donor- specific Tregs are likely more effective. In a murine islet allograft model, after recipient pre- conditioning by T cell ulection, transfer of fewer donor- reactive than polyclonal Tregs accesive d indetermite graft survival. Thighding lights sur potentiof antigencis -specif antigencif, whete, whech caid exped introne insthene insthene insthene et.

Te cele są prezentowane przez wszystkie grupy, które są obecne w ramach programu "Horyzont 2020", a nie w ramach programu "Horyzont 2020".

Chimeric Antigen Receptor Tregs: Rewolucja Approach

One of thee most exciting recent developts in Treg these interiering of chimeric antigen receptor (CAR) Tregs. The authors generated CAR Treg cells that premened human leukocyte antigen (HLA) -A2 (A2- CAR Treg cells) and cotconferred them with patogenec, islet- reactive effector T cells intro mice transplanted with HLA2-expressing islets. When the A2-CAR Treg cells were included thee transplantation setup, thels were protectles were tee never ted fr killing the cotred tor cells.

Thus, A2-CAR Treg cells can indukowane linked supression and long-lasting tolerance to a distinct autoimte antigen. Tolerance to te autoantigen does note require A2-CAR Treg persistence, indicating thee presence of infectious tolerance. Overall, these data demontate that A2-CAR Treg cells havec theraveutic use te to controlle both allo- and autoimmunoy in islet transplantation. Thiers phenvisonoun ous of infectious tolerante, whre care tregs induche long-lastintine protectinon evévén evter they ne ne neste, present, paragen present, paradigshin transftift transgent transgent transgentiont.

CAR- Tregs exhibited superior graft- protective properties compared to unmodified or polyclonal Tregs. HLA- A2- specific CAR- Tregs consistently impromently graft survival, reduced difficinatory cytokines, and supressed immate cell infiltration across skin, heart, and patic islet transplant models. These precinical findings have generate considerable excitement about thee potentional for CAR Treg therapy te eliminate thene ned for chronic remplivymone ressin klinicine in islet transplantaon.

Clinical Translation of Treg Therapy

Clinical trials of Treg therapy to date have primaryly tested autologous polyclonal, ex vivo- expanded Tregs showing excellent safety andd toleranty toe. Early -faxe clinical trials have demonstrantated that Treg infusion is safe andd well-tolerant in transplant recipients andd patients with autoimpete diseaseaseases. However, acquiing consistent clicate efficacy has proven more contriing, likely due te te use of polyklonal rather athn antigent -specific Tregs and thee neeze zoptymacje dosing ang tich meng.

Several clinical trials are currently underway to evaluate thee safety andd efficacy of Tregs wigh thee use of donor- specific Tregs, and strategies to expand Tregs in vivo after transplantation. Thee result of these trials will be cucial in determinaing whether Treg therapy cate standard of kliniclen. Thee result transpartion proplantion.

Costimulation Blockade: Interrupting T Cell Activation

T cell activation wymaga dwóch znaków: rozpoznawania on of antigen presented on MHC presentes (signal 1) and engagement of costimulatory providules (signal 2). Blocking costimulatory pathways presents an attractive strategy for preventing T cell activationin and promoting transplant tolerance without the broad immunosupression associated with conventional drugs.

CD28- B7 Pathway Blockade

Tllarly, thee cytotoksyc T lymphocyte antigen 4 immunoglobulin (CTLA4- Ig) fusion protein, which competitively blocks the CD28- B7 pathaways, was shown to inhibit T cell activation and prevent allograft rejection in skin, cardivac, liver, and islet transplantation. CTLA4 -Ig (belatacept) has been aprovided for use in kidney transplantation and has shown disee in precinical islet plantanon studies. By blocking the interactive n netween CD28 on cells and Bln Bantigens -presents, CTLAg cells.

Inne twierdziły, że te działania nie są obecne w ramach programu Of B7: CD28 and CD40: CD40L co- stymulujące blokady, te supressive function of CD4 + CD25 + Tregs was activated, supressing the proliferation of CD4 + effector cells. Experiments in vitro found that co- stymulatory blockade primed Foxp3 + Tregs two be more supressive than naïve Foxp3 + Tregs. Thi synergy between costimulation blocade and Treg functiontion suphests thatt combination approvises mativacine speciarlltive. Thi spective. Thi synergne demplance.

PD- 1 / PD- L1 Pathway Modulation

Targeting thee PD- 1 / PD- L1 pathway was shown to regulate and delay imtents an important imtente checkpoint that normally functions to limit excessive impetise responses and d prevent autoimmuntity. In transplantation, upregulation of PD- L1 on transplanted cells or exeliry of PD- L1 tte graft site cample PD- 1 on cells, upregulation of PD- L1 on transplanted cells or exerity of PD- L1 tte graft site campe PD- 1 on T cells, exering tribuillignals thors thattens thattens supres thel actios ther actioniton.

In addition, PD- L1 and CTLA4- Ig have been demonstranted to inhibit T cell activity in a nonshortant way. Despite these volung developments, thee PD- L1 or CTLA4- Ig was of ten administrative systemically and d cause nonspecific immune responses and immuno- related toxity. Thus, there e is great interest in amented delived of immunomodulatory accorporalys and localizatiod regulation of immunome responses with in thre graft microment.

Inżynier Mesenchymal Stromal Cells for Local Immunomodulation

Here, we engineer programmed death ligand-1 and cytotoksyc T lymphocyte antigen 4 immunoglobulin protein-modified mesenchymal stromal cells (MSC) as accessory cells for islet cotransplantation. The equirerd MSCS (eMSC) improwizuje ten execome of both syngeneic and allogeneic islet transplantation in diabetic mice and result in allograft survidval for up to 100 days with out any systemic immunodession. This approach represents ant lutin elgent solototototototin té té toc toxic toxity combated witcoatte witcoont blokerene, thent, ther implets enti enti.

Immunofenotypowy ping revealed reduced infiltration of CD4 + or CD8 + T effector cells anded infiltration of T regulatory cells with in thee allografts cottransplanted with eMSC compared ton controls. Te wyniki sugerują, że te eMScs can indukują lokal immunomodulation and may be applicable in clinical islet transplantation te reduce or minimize thee need of systemic immunosupression and ameliorate negative impt.

Genetic Engineering of Islets for Immune Evansion

Recent approvalities for creating quentiquent; hypoimmunogenic quentiquent; is lets that can evade immunie recovection and d destruction. This approvach aims to modify islets att thee genetic level two reduce their immunogenicity while reserving their insulin- secretg functiontion.

Strategia modyfikacji HLA

Hipoimmunogenic islets can generated with ablation of HLA expression while maintaining HLA- G and, and overexpression of PD- L1, or CD47. By deleting genes encoding classical HLA classicas I and class II cevidules (B2M and CIITA, respectively), research chers can create islets that are less visiblee te te recipient 's immunome system. However, complete absence of HLA Avisules cain trigger natural (NK) celllllllllse rejected, rejected, cells Ncells normallle expresenzelzed.

Te adresy to: Sciences have developed strategies to maintain expression of non-classical HLA dicules such as HLA- E and HLA- G, which can inhibit NK cell activation while note triggering T cell responses. More recently, Hu et al. reported that allogeneic transplantation of genetically expereid hyophyImpere -islets (B2M − / -, CIITA − / -, CD47 +) in diabetic nonhumane primates resuresult ted n ful reventiment, stable entíne, and incine, incinexincine, and inciutt, inciliun indibut tribut tribute triggere ingen ante ingen ingelle ingelse enti.

Clinical Breaktraphh: Hipoimmunologia Islets Without Immunosupression

On Jan 7, 2025 (Sweden), Sana Biotechnology released signical signical data: thee first person with type 1 diabetes (T1D) who received decasead donor islets establerd to evade the imty systeme is producing insulin with out immunosupression. This landmark resurements a major memone in thee field of islet plantation and demonstrantes thee diplobility of thee hyophyimmunone approviache in humas.

After 60 weeks, the single participant has reported d no searte or unexpected adverse events, meeting the trial 's primary safety endpoint. At 14 months after transplantation, thee participant continued to produce dictable C- peptide, indicating that the transplanted cells decloped alived functional. While this is early date from a single patient, it providesical proof concept that gened, immunoveasivesivesletcae iond function hums need in hums need for inmussivesivese drugne drugs.

Podczas gdy still very early, te znaleziska zapewniają important proof of concept that gene- edited, immuno- evasive islet cells can and d function in a person with T1D. If confirmed in larger studies, this approvach could help move field closer to cell these work thatt with long-term imte supression - a major goal thee future of T1D cres.

Localized Immunomodulation Through Cytokine Secretion

To enhance imtente evasion, the research chers developed dem cell- derived islets that secreted a combination of immunomodulatory cytokines: interleukin- 10 (IL- 10), transforming growth factor beta (TGFβ), and a modified IL- 2 (IL- 2 mutein N88D), designante te to selectively expand Treg cells. This strategy created a local immunosupressive environmentation at thee graft site, active stem cell- derved islet survival and functiont. Thi acception.

On thee tee tell hand, anti-emplatione cytokine IL- 10 can promote graft survival by modulating thee innate immunole response, as demontate te of transplantation. By emplaring islets to continuously secrete these protectiva factors, research chers can accee sustaved establed local immunomodulation with out they need for recated drug administration.

Encapsulation Technologies: Physical Barriers to Immune Attack

Encapsulation represents a fundamentally different approvach to protecting transplanted is lets frem imty rejection. Rather than modulating thee immate responses, encapsulation creates a physical conserver that prevents immate cells andd antibodies frem reaching thee islets while allowing the passage of dietients, oksygen, and insulin.

Principles of Islet Encapsulation

Te same wyzwania, innowacje, takie jak: ankietowanie, uniwersalna komórka, i immurodulatoryjne strategie, ane being developed to leaminate immune rejection and prolong thee functionion of thee transplant. This review outlines thee contemprary challenges in trzustka β cell therapy, specilarly impetione rejection, and recent progress in imteamenteon devices, hyophyimmunogenic stem cells, and regulatiof transplants. Theide encsul enculation material muse biobable, diffically stable, and havely controviselle preciselled exabiselled.

Various materials have been explored for islet encapsulation, including alginate, agarose, and synthetic polimers. Alginate, a naturally derived polisaccharide, has been the most widely studied material due te to biocompatibility, exe of gelation, and ability to form stable capsule. However, dimenges revin in acceining optimal capsule size, preventing fibro tic overgrowth, and ensuring ate oxygen and nuent suple appensulted.

Macroencapsulation Devices

Macroencapsulation devices contain multiple is within a single, larger chamber tam jest chirurcally implanted andd retrivevevid if necessary. In 2023, Vertex received thee approval of thee FDA to conduct a faxe 1 / 2 clinical trial for its texr product, VX- 264, which employs a unique strategy. It uses these same pantatic stem cells as VX- 880, but these cells are encapsulate with a operative imtable canalse -arterive avitavitative device tselle tsheld them fem from these 'imte imte cells are encene enceste.

Macroencapsulation devices offer separages, including the ability to retriceve thee device if complicicaties arise and the potential for prevascularization to o improwise oxygen and dieteent supply. However, they also face requilenges related to device biocompatibility, fibrotic overgrowth that can activition, and the need for operacical implantation and potentival removal.

Mikroencapsulation Approaches

Mikroencapsulation involves coating individual islets or small clusters of islets with a thin layer of biocompatible material, typically alginate. This approach offers a higher surface area-to-volume ratio compared to macroencapsulation, potentially improwing g oksygen and dieteent diffusion. Microencapsulated islets cane be transplanted via minimally y invasivative proceres, such such ais injection into the othealoneel cavity.

Despite these providenges, microencapsulation faces signitant contargenges. The capsules can trigger body responses leading to fibrozic overgrowth, which compatis islet functionon andd survival. Additionally, ensuring long-term capsule stability and preventing capsule rukture that would expose islets to thee immunome system meat ongoing concerns. Researche actively working to develop next- generation encapsulation materials with imped biocompatibility and antifibro.

Biomaterial- Based Immunomodulation Strategies

Beyond simple physical barriers, advanced biomaterials are being developed to actively modulate thee immunole response at te transplant site. These materials can deliver immunomodulatory drugs, present tolerogenic signals, or create microenvironments that promote immate tolerance.

Controlled Release of Immunomodulatorya Agents

Te mosty wspólne badania polimeraz biomatrial is poly (lactic- co- glikolic acid) (PLGA) as it is used in multiple FDA approved cancer therapies and has served thee delivy velle for thee formulation of multiple tolerance-inducing therapes. Biomatrials strategies for promoting islet transplantation tolerance typic ally focus on twos adprobaches: thee controlled relase of small medule drugs and proteins, and thee concovenigation of immunoulatordigi.

PLGA scaffalds ce loaded with various immunomodulatory agents, including ding anti- phandimatory drugs, tolerogenic cytokines, or costimulation blocking antibodies. By controling the degradation rate of thee polymer, research chers can accesse sustaved, localizase of these agents ate transplant site, provising prolonged immunoprotection with out thee need for systemic drug administration.

Podsumowanie, PLG scaffalds can serve as an concludive delivy system for islet transplantation that allows for thee co- localization of immunomodulatory cells with in islet grafts anddices long-term graft survival in an autoimte diabete model. This method of co- localizyng immunomodulatory cells with islets in a clinically translatable transplant site two affect thee immunome system on a local and systemic level has potentil therapeutic implications for human islet transplantation.

Immunomodulatorya Nanopaterles

Liu et al. used injection of immunomodulatory nanopancelt to remodel thee extrahepatic spleens of T1DM mice into a more hospitale transplant site that supported thee gravenftment, vascularization, and function of transplanted allo- and ksenogeneic islets. Proof- of- concept transplants of human islets into macaques on difficet of immunosupression further advocated for thee accepte. This innovative stratetes demontates hoatrialcas bese note only protect tlets but but aktyve developels develop deposites in hoatrialcaterialcates bés bées bélt.

Nanopationles offer excepte favorages for immunomodulation due to their ability to target specific imty cells ande deliver payloads wigh high efficiency. Researchers have developed nanopanceles that can selectively target antigen- presenting cells in limph nodes, deliving tolerogenic signals that promote the development of regulatory imtense responses. Other nanopenciode formulations can encapsulate donor antigens along with immunomodulatory drugs, inducing antigentific tolerantion with out bresian.

Surface Modification wigh Immunomodulatory Ligands

Another biomateriative strategy involves modifying thee surface of scafolds or encapsulation materials with immumodulatoryjny ligands. These ligands can include PD- L1, FasL, or tell context that deliver hamujący sygnał to impete cells upon contact. By presenting these signecals directly athe graft site, research chers can cade a local immunosupressive microenvironmentant that protecutics transplanted islets while reservivic systemicy immunology.

Surface modification can also be used to promote vascularization of thee transplant site, which is ccial for long- term islet survisval and function. incorporating vascularization strategies is proven to promote graft survisval, accessiate cell maturation, and overall enhance and suin function, which could be a beneficial next step. Materialcan be functionalization with pro- angiogenec factors or desid with specific topophas provathat provomeontrov vessel rowh, ensuring negate oxygene and nutene expletted transletted.

Alternatywa Przeszczepienie Sites andTheir Immunological Implications

Te choice of transplantation site can signiconsignitantly impact islet survival and function. While te portal vein has been thee standard site for clinical islet transplantation, contritivee sites are being explored that may offer immunological and functiondages.

Limitations of Portal Vein Transplantation

Replacement of β cells by allogeneic islet transplantation via portal vein has established in clinics all over the term d and shown to improwize glycemic control among patients. However, portal vein transplantation has several districbacks. The instant blood-mediated activory reactionion (IBMIR) causes diment early islet loss. Additionally, islets transplanted intro the liver are expose tted tcentrations of resive drugles, whch cah cae toxic, and tsynchs and negents and drugs fine the gastroense, thinen, hen, ht, ther function.

Te wszystkie ograniczenia środowiska sprawiają, że nie ma trudności z monitorowaniem transplantacji, są one w stanie zapewnić lepsze warunki, które są możliwe do przetrwania, a także funkcjonowanie, które mogą potencjalnie przyczynić się do immunologiki.

Thee Omentum andd Subcutanous Sites

Te omentum, a fold of otrzewnej nie wiszą from te stomach, has been explored as an exploretiva transplantation site. It offers good vascularization and accessibility for monitoring and potential l retrigevascularization strategies or thee use of scaffolds to support islet survival.

Subcutanous sitees offer thee subcutanous of easy accessibility for implantation, monitoring, and potential l retrievail. However, thee subcutanous space typically has pour vascularization, which can limit islet survival. Researchers have developed various strategies to overcome this limitation, includang prevascularization devices, angiogenec factor delivery, and the usie of scaffolds that provoroid vessel ingrowth.

Thee Spleen as an Immunomodulatorya Transplant Site

Islet transplants growing in tissue-remodeled spleens replace normoglycemia in diabetic mice and macaques. The spleen presents a specilarly-remounded ing transplantation site due te tich unique immunological contributies. A a secondary lymphoid organ, the speen concentrations of immunomodulatomy nanopantionles, the spleen cabe transformed inta tolerogent envisfer, when conditionion with immunomovulatory nanopantionles, the spleen cabe transmed inta.

Thi study supports further safety and d efficacy testing of thee remodeled d spleen as an islet transplant site for ameliorating insulin-departient-departicis. The ability to o leverage thee spleen 's immunological contributies to provote tolerance rather than rejection represents a paradigm shift in thinking about transplantation sites and highlights thee potentional for site- specific immunomodulation strategies.

Stem Cell- Derived Islets: Adresat thee Donor Shortage

Of thee major limitations of islet transplantation has been thee shortage of donor pancreata. However, thee limited acceptability of human cadaveric islet donors ande need the for ongoing administration of immunosupressive agents post- transplantation hinder thee widiespread usie of this treatment. Stem cell- derved islet organoids have emerged as an effective tvide corritiva tte to primary human islets. Thee develoment of prometis o generate functionl is fön huts fripotent stels pristents a major reents a major brecht brecht brecht brecht thubreakt thatch moubreag maet maispreg maet mai@@

Zaawansowane in Stem Cell Differentiation Protocols

Research ch over thee pact decade yielded an enriched pawiatic progenitor populatior and promoted their ir developmental potential to wards beta cell fate. The procols generated vary dependiing on te stem cell line and culture conditions. The most prominent procomes are optimized for hESC lines H1, HUES8, MEL1, and CyT49, and their deriative reporterr lines, ais monoiveron ates. These procomed cain noate islette clusters thats respond tose glucotis extretation and secrete insuline allly.

Niezwykle ważne jest, aby pacjent osiągnął poziom bezpieczeństwa w ciągu 75 dni i nie podtrzymał poziomu 98% czasu - w -range glycemic control for a year, wigh glycated hemoglobobin (HBA1c) reduced to non-diabetic levels. While thee approvach used patient- specific CiPScs, thee pacient waedirecving immunosupressive drugs in connection with previous allogeneic organ transplantation. This clical suctes demonsates that stem cell -derived islett action acffition effitivils, providens a providens a proof fof concepcifications foache.

Immunological Rozważania for Stem Cell- Derived Islets

Nvelles, implementing thi cell replacement these therapy still requires chronic immune supression, which may result in life-long side effects. Tu adresuje się te wyzwania, innowacje such as encapsulation devices, universal stem cells, and immunomodulatory strategies are being developed to companiate impete rejection and prolong thee function of thee transplant. Stem cell- derved islets face thee immunological providenges averic lets, includinting both alimmunone and autoimmunone rejection typne ypne 1 diabetes patientes 1 diabetes.

However, stem cell- derived is lets also offer unique applications for immunomodulation. Because they ay generated in vitro, they can e genetically modified befor e transformation te enhance their immaine evasion contrities. These studies indicate that thee modification of islets or stem cell - derived islets contrigh genetic extriering can induche locazized imtende tolerance ande enhance and enhance graft survitat thee for continues immunhempsin. Fure experioncre case agets.

Universal Donor Cells

Te koncepty nie są w stanie przedstawić; uniwersalna nie ma znaczenia; cells nie może być transplanted into any recipient with out triggering imtent rejection represents the ultimate goal of cell therapy. By combinang multiple genetic modifications - including deletion of HLA class I and II metiules, expression of non- classical HLA equilules, and overexpression of immunomoulatory proteins like P- L1 and CD47 - research chers are ing o create stem -requivelved islets thev evadene.

Breakthraugh T1D believes the bett chance for T1D cures lies in stem cell-based therapies Since decaseased donor islets are in short supple, while stem cells -derived islets can be produced at scale. Engineering cells to evade intack is a new path forward to protect the insulin- producing beta cells and avoid the use of immunosuprestrants s. Most importanty, this technology is being studied o appeny two stem cells -based therecies, which ich ible solution for many more mure vith.

Combination Strategies: Synergistic Approaches to Immune Protection

Coraz więcej, badacze rozpoznają, że nie jest to jeden z tych, którzy mają Immunitemodulatoryjny strategiczny may be suppenent to osiągnąć długoletni-term jest graft survival bez uodpornienia. Instad, combination approaches that adress multiple aspects of thee impete responses aneously may be necessary.

Integrating Cell Engineering with Biomaterials

Znaczenie, liberyjski lek immunosupresyjny, który może osiągnąć via generation of hypoimmunogenetic SC- islets or ingeldering an immunomodulatory transplantation microenvironment. Combination g genetically modified islets with immunomodulatory biomatterials could provide multiple layers of protecterion. For example, hypoimmunogenic isletcould bee transplanted ocfald over thatt deliver toleroic kinene and provoloterization. For example, hyimmunogenic isletcould bee transplanted ofold thet deliver teroic cytogens kinene and provolarizationizon, creationg olng optimal micotonnol.

This multi- pronged approacs different aspects of thee rejection process: genetic modification reduces thee initial impete requirection of islets, biomaterield imperatory supres local impete responses, and vascularization strategies ensure accerate oksygen and dietient supple for long- term islet function.

Combinang Cellular Therapies

Te co- transplantation of is lets with immunomodulatory cells presents anotherr rockinination strategy. More recent advances in is plantation derite from islet encapsulation devices, biomaterial platforms releasing g immunomodulatory compounds or surface-modified with impete regulating ligands, islet concering and coplantation with accolicory cells. Below, we comparade thee recent precinical research ch in immunomodulation viaterialsbased proviaches isériingen ingen. Below, we, we, we comparadirecorlation then comparation-compulation-compulation, altois, ishes seltene 'enses sene' ensetts 'ensetts' ense@@

Mesenchymal stromal cells, regulatory T cells, or tolerogenic dendritic cells could be co- transplanted with islets to provide local immunosupression and promote toma tolerance. These accessory cells can secrete anti- optimatory cytokines, supres effector T cell activation, and promote thee development of regulatory immunome responses. These consions lies in optimizing thee ratio of islets to immunomodulatory cells and ensuring that both cell type periode and actione effectiontex afteur transplantion.

Temporal Sequencing of Interventions

Te trzy przykłady, agressive immunosupression or T cell ubytek ten czas transplantation four accesiing optimal outcomes. For example, agressive immunosupression or T cell ubytek atte time time of transplantation could create a window of oportunity for tolerance incrite induction, followed by thee administration of regulator T cells or tolerogenic vaccines tano estivisish long-term tolerance ther regulator. Thi accompach air aims to preventain thee initial priming of alloactive T cells whille neaneouy promotiong thalment.

Furthermore, ratG treatment has been shown to promote expansion of distriveral Tregs which likely contribud to te faster kinetics of Treg reconstitution in ratg-treved patients over basiliximab-treatherad patients. In a comparative study of islet allograft transplant recipients addiving ether αCD25 or ratG induction these Tregets, ATG recipiens maintained a stable percipency of CD25 + CD4 + T cells, whereas these trepency of these Tregets treged ned ned negent αCD25 inductions.

Monitoring andBiomarkers for Transplant Outcomes

As immunomodulatory strategies has beste more explorated, thee ability too monitor immunole responses andd predict transplant outcomes becomes increamingly important. Developing reliable biomarkers could enable personalized immunosupression, when e treatment is tailored to each patient 's individual immunome response.

Immune Monitoring Technologies

Te fenotypowe cechy charakteryzation of T- cell subpopulations in these context of islet transplantation has revealed potentials for immunomodulatory thee potential of these cell type for improwing g transplantation outcomes to dissect thee incorporate for factular mechanisms, gene expression profiles, biological pathway alternations, and intercellulaar communicators among T- cell subgroups in both allogeneic and syngeneic islet transplantation models. Thiech provised a highresolution w of heterogened divitagen ittene divittene inthetertec intheterttelnhs -coml-communitill, tec.

Advanced technologies such as single- cell RNA sequencing, mass cytometry, and T cell receptor sequencing are provisiing unprecedented insights intro the immunoe responses to transplanted islets. These tools can identify specific T cell populations associated witch rejection or tolerance, track thee evolution of immunose responses over time, and potentially predict which patients are risk fr graft loss.

Non- Invasive Graft Monitoring

Developing methods to monitor the grafts in vivo andd conducting head- to- head comparasons of transplant outcomes across various sites in research ch settings could also help identify optimal conditions for long-term efficacy with potentional for clinical translation. Thee ability to non-invasively monitor islet graft function and early signs of rejection would be invicuable for clicameampement. Researchers are exposorinning various approviding, inding speciong techniques, cyrquirink bioarkers, and donorked corved cellved a nféll-free.

C- peptide levels remain thee gold standard for assessing is let function, but t they provide e limited information about thee mechanisms underlying graft dysfunctionion. Me experimentated biomarkers that can differencish between different causes of graft failure - such as immune rejection, recurrent autoimmunity, or metabolt exclustion - would enable more pretent intervents to conservene graft function.

Clinical Trials and d Regulatoryy Consignations

Translating innovative immunomodulatory strategies from the laboratoria to thee clinic requires nawigating complex regulatoryy pathways andd conducting rigorous clinical trials to demonstrante safety andd efficacy.

Current Clinical Trial Landscape

W tym przypadku należy uznać, że nie ma żadnych dowodów na to, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, można stwierdzić, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, można stwierdzić, że nie można stwierdzić, czy istnieje prawdopodobieństwo, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, można stwierdzić, że nie można stwierdzić, że w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, nie można stwierdzić, że nie ma potrzeby, aby w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, w przypadku braku odpowiedzi na pytania, Komisja nie podjęła decyzji o wszczęciu postępowania.

Numerous clinical trials are currently underway testing varioos immunomodulatory approaches, including tv treg therapy, encapsulation devices, and stem cell- derived islets. These trials face unique conquidenges, including thee need for long-term follow-up to assses durability of graft functionion, thee difficulty of comparaing outcomemos across diffiant procontribut and patient populations, and theh costs actisated with cell therapy producativiturining control.

Regulatory Pathways for Cell andGene Therapies

In thee USA, allogeneic islet transplantation is regulated the FDA as a biological drug under thee Biologics License Application (BLA) pathaway. Thi classification mandates extensive clinical trials, considency in producturing, and strict adsirence te o safety and efficacy standards, including higcosts, approvail ays, and limited accessibility and long-term safety, it comes with difficienges, including higcosts, approvil delayd.

Genetically modified is lets andd CAR Treg therapies face additional regulatory controlly as gne therapy products. Demonstrating thee safety of genetic modifications, ensuring thee absence of off- target effects, and establingg long-term safety monitoring ogr promeths are all essential requirements for regulatory approvation. Thee complex of these requirements cans can slow thee translation of difficinang therazies from precinical studies to clical applicatication.

Producturing andScalability Challenges

One key issue is scalability. While the differentiation protocol used to generate islet- like cells showed high efficiency, translating this process into a scalable, cost- effective production system for widnespreaad clinical use pose signitant logistical andd economic consistenges for millions of pacients in the autonous setting. Produktituring cell theraies att clicicical sale while maing consistent quality and functiont represents a majoint for theld.

For autologous therapes like patient- specific CAR Tregs, thee producturing process must be repeate for each individuat patient, which ch is time- consuming andd costsive. Allogeneic approvaches using universaval donor cells could potentially overcome these limitations by enabling off- the- shelf acvability, but they require more extensive genetic modifications to prevent rejection. Developg automate, closed-system producting platforms and emplig rigorous quality commerdiards wille bess for king these these accessible accessible accessible bble.

Future Directions andEmerging Technologies

Te wszystkie immunomodulation for są nadal transplantationami, które ewoluują, witch new technologies and d approaches emerging that promise to further improwize out comes.

Artificial Intelligence andMachine Learning

Artificial intelligence and machine learning are beginning to be applied to transplantation immunology, wigh the potential to previdal rejection risk, optimize immunosupression protocles, andd identify novel therapeutic targets. By analyzing large datasets frem clinical trials andd patient registries, machine learning algorythms could identify Patterns andd biomarkers that are not tat thragh traditional methitail approaches.

Mogę też wykorzystać te programy, aby określić optimal combination immunomodulatory strategies, przewidywać, że kombinacje of genetic modifications, biomatarials, and cellulair therapies are most likele te succed for individual patients based on their ir impete profiles andd clinical criphisties. This personalized medicine approvach could maximize thee chances of acquiling long-term graft survival while minimilyzing thee risks of immunosupression.

CRISPR and Advanced Gene Editing

CRISPR- Cas9 and teor advanced gene Editing technologies are enabling experimentations modifications of islets and imty cells. Beyond simpliche gene knockouts, research chers are now using base editing and prime editing to make precise changes to individual nucleotides, potentially correcting disease -causing mutations or optimizing gene expression levels.

Multiplexed gene editing, where multiple genes are modified consideraneousy, is enabling thee creation of islets witch conclussive impetition evasion properties. Future iterations might included none only HLA modifications and d immunomodulatory protein expression but also enhanced resistance to o efficulmatory y cytokines, improwized glucose sensing, and progresied insulin secation capity.

Organoid andBioprinting Technologies

Trzy-wymiarowe bioprinting i organoid technologies are opening new possibilities for creating more physiologically relevant islet constructs. Rather than transplanting dispersed islets, research chers are exploring thee creation of patiatic organoids that more closely mimic thee nativa pantiatic architecture, potentially improwiting function and survidval.

Bioprinting mógłby wprowadzić te precise arangement of islets, vascular cells, and immunomodulatory cells with win constructie tissue constructs, creating optimal microenvironments for graft survival and functionon. These constructs could be designate with with built- in vascular networks to ensure consumplate oxygen and nudient supply from thee momento of transplantation.

Xenotransplantation Advances

Porcine jest coraz bardziej prawdopodobne, że ten potencjał jest jeszcze bardziej skomplikowany, ale ten problem nie jest jeszcze jeszcze bardziej skomplikowany. Recent advances in pig genetic incordering, including the knockout of genes encoding xenantigens ande expression of human complement regulatory proteins, have difficultantly improwise the survival of porcine islets in precinical models. While xensurvisaltation faces unique immunological consistenges, including the need to overcome cellular and anticibedisated rejectione, continene progresis is a could converevils convertion could provide an unlimited sued undeple suple suple suple oletfos.

In Vivo Reprogramming

Nie ma mowy, żeby ktoś z nich był w stanie to zrobić.

Wyzwania i Barriers to Clinical Translation

Despite the extreminable progress in immunomodulation for islet transplantation, signitant challenges remaine befor e these advances can be widely implemented in clinical practice.

Cost andd Accessibility

Advanced cell and gene therapie are extremely locsive to develop and productures, raising concerns about accessibility and health equity. The coss of CAR Treg therapy, genetically modified islets, or experimentated encapsulation devices may be prohibitiva for many patients andd healthcare systems. Developing strategies to reduce producetes producturing costs andd demonstranting costreats compared to felong insulin themy and management of diabetetes complicamento will bee essentil for widnespred adention.

Koncerny Długotermalne Safety

Te długie-term safety of genetically modyfied cells kees a concern, specilarly responding thee potentional for inserctional mutagenesis, off- target gene editing effects, or uncontrolled cell proliferation. Ustanowienie kompleksu długoterm safety monitoring procompats anddeveloperg safety changes that allow the selective elimination of transplanted cells if problems arise will be important for regulatory acceptail ance and patent approvisance.

Standardization andReproducibility

Te kompleksy of man immunomodulatoryjne strategie make s standaryzation and reproducibility difficiing. Protocs for cell isolation, explosion, genetic modification, and transplantation mutt be rigorously standardized to ensure consistent comes across different centers andd patient populations. Ustanowienie international registries andd collaborative networks to share procomed and comparate out comes will be important for advancing the field.

Patient Selection and Risk- Benefit Assessment

However, systemic immunosupression, requid to prevent allograft rejection, may be toxic to islets and, more importantly, has deleterious side effects to patients. Og note, for most T1D pacients, thee systemic immunosupression is riskier than long-term standard management witch exogenous insulin suppresentation, which most makees eliminating systeming immunosupression critional to β cell revevement theraies. Determinang whch patients are meline mely o benet is plantat transtinon and which immulatorneaches aches aches ates.

Patients wigh sere hypoglycemia unwaureness and those already received kidney transplants (and are thee need for systemic immunosupression) are clear candidates for islet transplantation. However, as immunomodulatory strategies improwizuje and thee need for systemic immunosupression propes, islet transplantation may mee appropriate for a brower range of patients. Developineg tools to assess individuail riskenet profiles and previct whf patis are mely mely likely tre-term sucére sucres. Develophavess be importanfur zoptent.

Thee Path Forward: Integrating Research and Clinical Practice

Recent emprents can be broadly categorized into: (1) improwing the cell product as surrogates of nativa beta cells, (2) promoting grawerftment post- transplant to support cell survival, integration into the host, and endocrine functionion, and (3) developg immunomodulation strategies to reduce or oversivent immunosupression regimen. In this review, we contains recent and emerging advancedes in these threaes and these potental, risk, and scalabity experiontal modele.

Te ultimate goal of immunomodulation research ch in is let transplantation is to accesse durable insulin independence with thee need for chronic immunosupression. While this goal has nott yet been fully realized in clinical practice, the rapid pace of scientific progress suggests that at it may be acceables in thee examinable future.

Współpraca w zakresie badań sieci

Advancing thee field require close collaboration between basic scientists, clinicians, biocompanies, and industry partners. Enstablishing collaborative research ch networks that can conduct multi- center clinical trials, share data and biological samples, and coordinate translational research ch emplets will bess essential for expecatiing progress. International consortia focused on islet transplantation and diabetetes cure revilcch are already playing important roles facipating these collaborations.

Patient Engagement andAdvocacy

Engaging patients andd advocacy organisations in research crisis priority- setting and clinical trial designan is cucial for ensuring that research ch efficients align with patient needs andd preferences. Patient input can help identify thee mott important out to mesidure, acceptable risk- benefit tradeofs, and considers to clicical trial participation. Organizations focused on diagetes research ch and cure advocacy are playing presignant rolein fung research, raing awings, aureness, aneses, anesents connectinents patients.

Regulatoryzacja Innowation

Regulatoryjny program terapii jest coraz bardziej rozpoznawalny, że potrzebne są nowe metody, które mogą być ocenione przez osoby, które nie są już w stanie przeprowadzić oceny. Adaptativa trial designs, surogate endispoins, and accelerate approvate aprovail pathaway may help speed thee translation of rossing therapes while maintaing approvate safety standards. Continue dialogue between revilchers, clinicisians, and regulators will important for developing regulatory frameworks that balance innovation patiety sapety.

Konkluzja: A New Era in Diabetes Treatment

This highlights the urgent need for novel interventions to prevent autoimte attack on β- cells and delay disease progression. In parallel, innovative strategies mutt bed developed to support the long-term survival of transplanted islets in advanced-stage patients with out systemic immunosupression, moving from broad, non-specific immunosupression toward experitene d strates made presentabale progresses in recent years, moving from broad, non-specific immunosupressiont ton tovalingly experitee d strates specific.

Te convergence of multiple technologicales advances - including ding gene editing, biomaterial equicering, cell therapy, and advanced immunologies - is creating unprecedented applicatities to overcome thee immunological consiners that have limited islet transplantation. Rapid advances and convergence of expertise in biomatrial sciences and immunology have led te development of multiple strategies aimed at inducing tolerance to allogeneic islets with thene need for systemic immunoton.

Recent clinical successes, including ding thee FDA approval of Lantidra and thee demonstration that gene- edited is lets can functionin with out immunosupression in human, provide proof of concept that these approvaches can work in clinical practice. While contrahenges accordions equin in terms of scalablity, cost, long-term safety, and accessibility, thee accorporacy of thee field is clearly toward more effective and less toxic approaches tting transport.

For patients with type 1 diabetes, these advances offer hope for a future when ere insulin independence can be accesed thee burden of chronic immunosupression. As immunomodulatory strategies continue to o improwize, islet transplantation may transition from a treatment reserved for a small subset of patients to a widely acceptable option for accessing diabetes cure. Thee integration of stem cell- derved islets with advanced immunomodaulatioon approvices could evalualle make functives.

Te next decade will be critical for translating thee wealth of precinical findings into clinical practice. Success will requires continued investment in basic and translational research, collaborative clinical trials, innovative regulatory approvaches, and sustained commitment from thee scientific community, healccare providers, industry partners, and patimels advantates. With these elements in place, thee goal of revisiing longg islet graft experivál resin - and timately, a functivail for type 1 dubes - ions - iont.

For more information on diabetes research ch and clinical trials, visit the indis1; dis1; FLT: 0 dis3; Sis3; JDRF (Juvenile Diabetetes Research Foundation) dis1; FL3; And Thee Sis1; Is1; FLT: 2 Sissplantation 3; Issortom 3; National Institute of Diabetes and Digmeine and Kidney Diseaseaseases Sis1; IGL 1; FLT: 3 Siscontail 3. Additional Resources on islet translet plantation cae found dishh sid; 1phagen; Is111L 3L; Islel; Islet; Islet: 3; Islet; PPPRIT; PRIT; PRID; PRID; P@@